[A multicenter observation study of the efficacy of cortexin and recognan (citicoline) in the treatment of cognitive impairments in chronic cerebrovascular pathology].
To make a critical assessment of the therapeutic effect of complex therapy with cortexin and recognan (citicoline) for cognitive impairments in patients with chronic cerebrovascular pathology. Presented is an analysis of results of the multicenter observation program to assess the efficacy of cortexin and recognan (citicoline) in the treatment of cognitive impairments in patients with chronic cerebrovascular pathology. Three hundred and nine patients with chronic cerebrovascular pathology, including 134 (43.4%) men and 175 (56.6%) women, aged from 30 to 80, average age 63.4±9.4 years, with confirmed cognitive deficit were examined. The diagnosis was established on the basis of complaints, case reports, the results of CT/MRI studies, as well as assessments of the neurological status and cognitive functions. Cognitive impairments were confirmed by the number of points on the Mini-mental state examination (MMSE) and the Clock drawing test. The assessment of depression was made with the Mini Geriatric Depression Scale (MGDS). All patients received cortexin and recognan (citicoline) ('Geropharm', Russia) at doses 10 mg/day for 10 days and 1000 mg/day for 1 month, respectively. Complex therapy with cortexin and recognan (citicoline) showed high efficacy in the treatment of vascular cognitive disorders. The results of the study allow us to recommend the complex administration of cortexin and recognan (citicoline) ('Geropharm', Russia) in doses of 10 mg/day for 10 days and 1000 mg/day for 1 month, respectively, for chronic cerebrovascular pathology.